61 Moulton Street
Bionaut Pharmaceuticals Inc.
Bionaut Pharmaceuticals is pioneering a predictive assay platform for drug discovery and lead optimization using engineered cell lines. The firm has established internal small-molecule discovery programs and partnerships in autoimmune/inflammatory diseases and cancer, and is expanding its assay capabilities into other diseases.
More from Archive
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.